High avidity anti-b2-glycoprotein I antibodies in patients with antiphospholipid syndrome
نویسندگان
چکیده
Objective: To evaluate avidity of IgG anti-b2-glycoprotein I antibodies (anti-b2-GPI) in patients with antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) in relation to thrombosis, and to demonstrate a possible affinity maturation of IgG anti-b2-GPI during the disease course. Methods: 64 sera from 32 patients (18 with primary or secondary APS, 14 with SLE without APS) and their respective IgG fractions or affinity purified anti-b2-GPI were studied by anticardiolipin (aCL) and anti-b2GPI enzyme linked immunosorbent assay and by chaotropic assay. Results: Six, 12, and 14 patients had high, low, and heterogeneous avidity IgG anti-b2-GPI, respectively. In 12 patients an increase in antibody avidity was observed over a period of between four and 12 years. More patients with APS were in the high avidity than in the low avidity anti-b2-GPI group, while the opposite was observed for SLE alone (both p,0.05). The most common clinical feature among patients with high avidity anti-b2-GPI was thrombosis, mainly venous thrombosis (p,0.05 and p,0.02, respectively, v the low avidity anti-b2-GPI group). Conclusions: Patients with APS with or without SLE may have anti-b2-GPI of high, low, or heterogeneous avidity. High avidity anti-b2-GPI appear to be associated with thrombosis and APS, while in pure SLE low avidity anti-b2-GPI may prevail. Monitoring of avidity may help elucidate the role of anti-b2-GPI affinity maturation in the pathogenesis of APS.
منابع مشابه
EXTENDED REPORT High avidity anti-b2-glycoprotein I antibodies in patients with antiphospholipid syndrome
Objective: To evaluate avidity of IgG anti-b2-glycoprotein I antibodies (anti-b2-GPI) in patients with antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) in relation to thrombosis, and to demonstrate a possible affinity maturation of IgG anti-b2-GPI during the disease course. Methods: 64 sera from 32 patients (18 with primary or secondary APS, 14 with SLE without APS) and th...
متن کاملRevisiting Beta 2 Glycoprotein I, the Major Autoantigen in the Antiphospholipid Syndrome
Beta 2 glycoprotein I (β2GPI) is a single chain 50 kDa highly glycosylated glycoprotein at an approximate concentration of 4 μM in cells. The abundance of this protein in plasma and its high state of preservation indicate the important role of this protein in mammalian. In addition, β2GPI has a particular structure in the fifth domain, and is categorized as the major antigen recognized by autoa...
متن کاملHigh avidity anti-beta 2-glycoprotein I antibodies in patients with antiphospholipid syndrome.
OBJECTIVE To evaluate avidity of IgG anti-beta 2-glycoprotein I antibodies (anti-beta2-GPI) in patients with antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) in relation to thrombosis, and to demonstrate a possible affinity maturation of IgG anti-beta 2-GPI during the disease course. METHODS 64 sera from 32 patients (18 with primary or secondary APS, 14 with SLE without ...
متن کاملAnti-b2-Glycoprotein I Autoantibodies from Patients with the “Antiphospholipid” Syndrome Bind to b2-Glycoprotein I with Low Affinity: Dimerization of b2-Glycoprotein I Induces a Significant Increase in Anti-b2-Glycoprotein I Antibody Affinity
متن کامل
Lymphocytopenia is associated with anti-Beta-2 glycoprotein-1 in patients with 220 systemic lupus erythematosus.
BACKGROUND Anti B2-Glicoprotein 1 (B2-GPI) is an antiphospholipid antibody that may be present in primary or secondary antiphospholipid syndrome (APS). Systemic Lupus erythematosus (SLE) is the main disease associated with secondary APS. OBJECTIVE To study the prevalence of anti B2-GPI in SLE patients. METHODS Anti B2-GPI (IgM/IgG) was studied by ELISA in 88 patients with SLE of both gender...
متن کامل